Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide companion diagnostic - Celgene/NanoString Technologies

Drug Profile

Lenalidomide companion diagnostic - Celgene/NanoString Technologies

Alternative Names: LymphMark

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation; NanoString Technologies
  • Developer Celgene Corporation
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diagnostic agents; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
  • 13 Aug 2019 Discontinued - Clinical-Phase-Unknown for Diffuse large B cell lymphoma (Diagnosis) in USA (unspecified route)
  • 31 Jul 2019 NanoString Technologies and Celgene Corporation terminated their collaboration for development of Lenalidomide companion diagnostic
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top